CSF2 and neoplasm: Some alternatives have been tested, including HSPs-pulsed dendritic cells[15], chaperone-rich cell lysates derived from tumors(CRCL) [23], combination with GM-CSF [18, 24], recombinant HSPs with tumor-associated peptides[25] or encapsulated in nanoemulsions [26] and have shown improved immunogenicity.